Treatment of recurrent vulvo-vaginal candidiasis with sustained-released butoconazole pessary

Heng LZ, Chen YJ, Tan TC
Correspondence: Dr Tan Thiam Chye, drtctan@me.com

ABSTRACT
Vulvo-vaginal candidiasis (VVC) is a common infection among women. 5% of women with acute infection experience recurrent vulvo-vaginal candidiasis (RVVC). There is currently no optimal or recommended regime for RVVC. Although antifungal agents, such as imidazoles, have been successfully used as a first-line treatment for acute VVC, its effectiveness is limited in RVVC. This could be due to patient factors, drug application (such as leakage) or dosing factors. A sustained-release (SR) bioadhesive vaginal cream (2% butoconazole nitrate) has incorporated VagiSite technology, a topical drug delivery system that allows SR of the drug. We describe its efficacy and the successful use of a butoconazole-SR formulation in the treatment of two cases of RVVC.

Keywords: butoconazole, candidiasis, recurrent vulvo-vaginal
Singapore Med J 2012; 53(12): e269–e271